Navigation Links
BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
Date:7/17/2009

tient's temperature and clinical condition. In this study, the median time to alleviation of symptoms in all 37 evaluable patients treated with either 300 mg or 600 mg peramivir daily was 68.6 hours.

i.v. peramivir 300 mg and 600 mg in both single and multiple doses were generally safe and well-tolerated in these trials. Further analyses of the study data, including secondary efficacy endpoints and detailed safety is underway. Additional data will be submitted for presentation at an upcoming medical meeting.

"The clinical outcomes of these Phase 3 studies are important, especially during the declared influenza pandemic, as they indicate the promise of peramivir as a treatment for influenza," commented Dr. William P. Sheridan, Chief Medical Officer of BioCryst. "The need for additional anti-viral treatment options for influenza remains high. BioCryst is currently finalizing its plans for peramivir Phase 3 studies intended to support U.S. regulatory approval, while continuing to support the pre-emergency use authorization review of peramivir by the U.S. Food & Drug Administration."

"This data represents a significant milestone for BioCryst -- the first Phase 3 studies successfully conducted with a drug candidate discovered by BioCryst," said Jon P. Stonehouse, President and Chief Executive Officer of BioCryst. "We congratulate Shionogi on the success of these rapidly completed studies, which have the potential to lead to the first regulatory approval for peramivir."

Shionogi has stated that the Company is making its best effort to file its New Drug Application and to receive a manufacturing approval as soon as possible in Japan.

About Peramivir

Peramivir is an anti-viral agent that inhibits the interactions of influenza neuraminidase, an enzyme which is critical to the spread of influenza within a host. Peramivir has demons
'/>"/>

SOURCE BioCryst Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
2. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
3. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
4. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
5. BioCryst Updates Peramivir Clinical Development Plan
6. BioCryst Provides Forodesine HCl Update
7. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
8. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
9. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
10. Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
11. Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 The spinal column is one of the ... carried to and from the brain through the column control ... Injury or ailment here can be life altering, and leave ... control over their body. Though back injury and disease can ... are more options available to make things better than ever ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - The Canadian Epilepsy Alliance ... comic series designed to educate children about the most common ... Medikidz Explain Epilepsy comic series tells a fictional ... navigating middle school while living with epilepsy. ... there is still so much misinformation and lack of awareness ...
(Date:8/21/2014)... , N.Y. and HAMBURG, Germany , ... announced it is collaborating with Deutsches Elektronen-Synchrotron ( DESY ... Germany , to speed up management and storage ... Big Data and Analytics architecture based on IBM ... per second of data at peak performance and help ...
Breaking Medicine Technology:Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3
... ROCKVILLE, Md., Dec. 16, 2010 Novavax, Inc. (Nasdaq: ... clinical trial to evaluate a new vaccine candidate to prevent ... U.S. Food and Drug Administration (FDA) and is no longer ... had received a question from the FDA regarding chemistry, manufacturing ...
... Resources, one of the world,s leading research and ... that, owing to its superb efficacy, acceptable safety ... Ironwood/Forest/Almirall/Astellas,s linaclotide will emerge as the market leader ... In 2019, linaclotide will garner blockbuster sales of ...
Cached Medicine Technology:NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial 2NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial 3NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial 4For Treatment of Irritable Bowel Syndrome, Linaclotide Will Emerge as the Market Leader and Will Achieve Blockbuster Status in 2019 2
(Date:8/22/2014)... 22, 2014 Natural Clear Vision , ... restore his own vision from legally blind to perfect 20/20 ... investigative review. , “There is a huge portion of ... everyday function, and most people just think that’s the way ... surgery that can be pretty risky at times,” reports Michaels. ...
(Date:8/22/2014)... deletion in advanced non-small cell lung cancer (NSCLC) ... in epidermal growth factor receptor (EGFR) tyrosine kinase ... BIM deletion independently predicts overall survival (OS) of ... activate the programmed cell death also known as ... been detected in 12.8% of the Asian population ...
(Date:8/22/2014)... Rheumatoid arthritis (RA), a complex autoimmune disease that ... patients to not only cope with pain, disability ... as disrupted work, family life and marital functioning. ... residual pain and disability is common. In addition, ... high cost or side effects. Because of this, ...
(Date:8/22/2014)... London, UK (PRWEB) August 22, 2014 ... more magnetic for some clinical applications due to ... of the emerging innovations in ultrasound, such as ... imaging, are expected to keep the market moving ... as increasing mobility can enhance not only the ...
(Date:8/22/2014)... Mueller Sports Medicine is excited to ... new product that provides non-drug instant relief for plantar ... you heal. The package includes 7 days of relief, ... – it is not kinesiology tape. It’s made in ... for Plantar Fasciitis is a breakthrough in the ...
Breaking Medicine News(10 mins):Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2
... New York City has discovered that chronic pain occurs as ... colleagues were studying chronic pain at the molecular and cellular ... and the neurons becomes excited and begin to send signals ... the stimulus is removed the nerves become dormant and there ...
... mantids – that is, the female praying mantid eats ... possibility that males may also have something to gain ... In a paper in the August issue of The ... male risk-taking behavior in a praying mantis by altering ...
... facial transplant patient was discharged for a week after undergoing ... , ,Li Guoxing, 30, who had not seen his wife ... Xijing Hospital returned home Friday for a week-long visit to ... part of his face is alive and Li has been ...
... most common medical condition, chronic widespread pain is ... associated with fatigue, depression and poor sleep.// ... cancer patients deveolping FM like symptoms after treatment ... studies have shown contradictory results. A new study ...
... tested HIV positive was tied to his bedpost at the Meerut ... April after committing a robbery. He tested HIV positive only last ... College, which proved to be hopelessly inadequate to deal with his ... ago when a blood test confirmed he was HIV positive. He ...
... Alma Garcia, 41, were well aware of the toll ... was suffering from high blood pressure, diabetes and thyroid ... ,When they scheduled their gastric bypass surgeries at ... 2006, they joined a growing number of severely overweight ...
Cached Medicine News:Health News:Insufficent Anti-inflammatoy Proteins Leads to Chronic Pain 2Health News:Weight-Loss Surgeries Changing Lives 2Health News:Weight-Loss Surgeries Changing Lives 3Health News:Weight-Loss Surgeries Changing Lives 4
PosiBlot 30-30 Pads...
... VacuGene XL Vacuum Blotting System ... gels up to 20 30 ... Efficient and reproducible transfers improve blotting ... in the unit. Precise vacuum control ...
... Pens-Using a proprietary and patented technology, ADI ... called Antigen-Antibody pens-TM, that will allow researchers ... in any form or shape or size. ... to see antigen being written on the ...
... Advantages of using the Antigen-Antibody Pens-Using ... designed and developed specialized fountain pens, called ... deliver or write/mark the blotting membranes in ... specially formulated antigen-bonded colored dyes helps to ...
Medicine Products: